Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum10634610.26442/20751753.2022.1.201475ReviewОбзорReview ArticleRational drug therapy of chronic heart failure: the role of mineralocorticoid receptor antagonists: reviewРациональная терапия хронической сердечной недостаточности: роль антагонистов минералокортикоидных рецепторовhttps://orcid.org/0000-0001-6624-3804SafronovaNatalia V.СафроноваНаталья Владимировна
Russian Federation

Cand. Sci. (Med.), Chazov National Medical Research Center of Cardiology

канд. мед. наук, мл. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова»

izhirov@mail.ruhttps://orcid.org/0000-0002-4066-2661ZhirovIgor V.ЖировИгорь Витальевич
Russian Federation

D. Sci. (Med.), Chazov National Medical Research Center of Cardiology, Russian Medical Academy of Continuous Professional Education

д-р мед. наук, вед. науч. сотр. отд. заболеваний миокарда и сердечной недостаточности НИИ клинической кардиологии им. А.Л. Мясникова ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», проф. каф. кардиологии ФГБОУ ДПО РМАНПО

izhirov@mail.ruhttps://orcid.org/0000-0001-9234-6129TereshchenkoSergey N.ТерещенкоСергей Николаевич
Russian Federation

D. Sci. (Med.), Prof., Chazov National Medical Research Center of Cardiology, Russian Medical Academy of Continuous Professional Education

д-р мед. наук, проф., первый зам. ген. дир., зам. ген. дир. по научной работе, рук. отд. заболеваний миокарда и сердечной недостаточности ФГБУ «НМИЦ кардиологии им. акад. Е.И. Чазова», зав. каф. кардиологии ФГБОУ ДПО РМАНПО

tereschenko@yandex.ruChazov National Medical Research Center of CardiologyФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава РоссииRussian Medical Academy of Continuous Professional EducationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России1501202224128351604202216042022Copyright ©; 2022, Consilium MedicumCopyright ©; 2022, ООО "Консилиум Медикум"2022Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/106346

Mineralocorticoid receptor antagonists (MRAs) are part of basic medical therapy for heart failure. The clinical efficacy of MRAs has been proven by randomized clinical trials. To review comparative efficacy and tolerability data between the two main MRAs, spironolactone and eplerenone, in patients with systolic heart failure.

Антагонисты минералокортикоидных рецепторов (АМКР) являются частью базисной медикаментозной терапии больных с сердечной недостаточностью. Клиническая эффективность АМКР доказана в рандомизированных клинических исследованиях. В данном обзоре проводится сравнительный анализ эффективности и переносимости двух основных АМКР, спиронолактона и эплеренона, у пациентов с систолической сердечной недостаточностью.

congestive heart failuremineralocorticoid receptors antagonistsacute myocardial infarctioneplerenoneхроническая сердечная недостаточностьантагонисты минералокортикоидных рецепторовострый инфаркт миокардаэплеренонRizzo C, Carbonara R, Ruggieri R, et al. Iron Deficiency: A New Target for Patients With Heart Failure. Front Cardiovasc Med. 2021;8. DOI:10.3389/fcvm.2021.709872Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-86. DOI: 10.1016/j.jacc.2017.08.074James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. DOI:10.1016/S0140-6736(18)32279-7van Riet EE, Hoes AW, Wagenaar KP, et al. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail. 2016;18(3):242-52. DOI:10.1002/ejhf.483Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. DOI:10.15420/cfr.2016:25:2Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572-80. DOI:10.1016/S0140-6736(17)32520-5McDonagh TA, Metra M, Adamo M, et al. ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-726. DOI:10.1093/eurheartj/ehab368Virani SS, Alonso A, Aparicio HJ, et al. Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021;143(8):e254-743. DOI:10.1161/CIR.0000000000000950Maggioni AP, Dahlström U, Filippatos G, et al. Heart Failure Association of the European Society of Cardiology (HFA). EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. DOI:10.1093/eurjhf/hft050Tsao CW, Lyass A, Enserro D, et al. Temporal Trends in the Incidence of and Mortality Associated With Heart Failure With Preserved and Reduced Ejection Fraction. JACC Heart Fail. 2018;6(8):678-85. DOI:10.1016/j.jchf.2018.03.006Chioncel O, Lainscak M, Seferovic PM, et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(12):1574-85. DOI:10.1002/ejhf.813Pocock SJ, Ariti CA, McMurray JJ, et al. Meta-Analysis Global Group in Chronic Heart Failure. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. Eur Heart J. 2013;34(19):1404-13. DOI:10.1093/eurheartj/ehs337Поляков Д.С., Фомин И.В., Беленков Ю.Н., и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. Кардиология. 2021;61(4):4-14 [Polyakov DS, Fomin IV, Belenkov YuN, et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiia. 2021;61(4):4-14 (in Russian)]. DOI:10.18087/cardio.2021.4.n1628Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;8:7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7-13 (in Russian)]. DOI:10.15829/1560-4071-2016-8-7-13Арутюнов А.Г., Рылова А.К., Арутюнов Г.П. Регистр госпитализированных пациентов с декомпенсацией кровообращения (регистр Павловской больницы). Сообщение 2. Клиническое значение и прогностическая роль некоторых параметров, определяемых при физикальном и инструментальном обследовании пациентов с декомпенсацией кровообращения. Сердечная недостаточность. 2014;15(2):67-75 [Arutyunov AG, Rylova AK, Arutyunov GP. Registry of hospitalized patients with decompensated circulation ("Pavlov’s hospital registr"). Report 2. Clinical significance and prognostic role of some parameters determined during physical and instrumental examination of patients with decompensated circulation. Russian Heart Failure Journal. 2014;15(2):67-75 (in Russian)]. DOI:10.18087/rhfj. 2014.2.1934Funder JW. Minireview: Aldosterone and Mineralocorticoid Receptors: Past, Present, and Future. Endocrinology. 2010;151(11):5098-102. DOI:10.1210/en.2010-0465Funder JW. Aldosterone and Mineralocorticoid Receptors in the Cardiovascular System. Prog Cardiovasc Dis. 2010;52(5):393-400. DOI:10.1016/j.pcad.2009.12.003Jaisser F, Farman N. Emerging Roles of the Mineralocorticoid Receptor in Pathology: Toward New Paradigms in Clinical Pharmacology. Pharmacol Rev. 2016;68(1):49-75. DOI:10.1124/pr.115.011106Kjekshus J, Swedberg K. Tolerability of enalapril in congestive heart failure. Am J Cardiol. 1988;62(2):67A-72A. DOI:10.1016/S0002-9149(88)80088-2Swedberg K, Eneroth P, Kjekshus J, et al. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82(5):1730-6. DOI:10.1161/01.CIR.82.5.1730Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70(4):479-87. DOI:10.1016/0002-9149(92)91194-9Tsuyuki RT, Yusuf S, Rouleau JL, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol. 1997;13(12):1166-74.McKelvie RS, Yusuf S, Pericak D, et al. Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators. Circulation. 1999;100(10):1056-64. DOI:10.1161/01.CIR.100.10.1056Хроническая сердечная недостаточность, клинические рекомендации Минздрава России, 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/156_1/ Ссылка активна на 11.01.2022 [Khronicheskaia serdechnaia nedostatochnost', klinicheskie rekomendatsii Minzdrava Rossii, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1/ Accessed: 11.01.2022 (in Russian)].Галявич А.С., Фомин И.В., Гайсин И.Р., и др. Подходы к терапии сердечной недостаточности со сниженной фракцией выброса. Резолюция онлайн-совета экспертов Приволжского федерального округа. Российский кардиологический журнал. 2021;26(S4):4791 [Galyavich AS, Fomin IV, Gaisin IR, et al. Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts. Russ J Cardiol. 2021;26(4S):4791 (in Russian)]. DOI:10.15829/1560-4071-2021-4791Maddox TM, Januzzi JL, Allen LA, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2021;77(6):772-810. DOI:10.1016/j.jacc.2020.11.022Bhatt DL, Verma S, Braunwald E. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metab. 2019;30(5):847-9. DOI:10.1016/j.cmet.2019.10.008Ferreira JP, Zannad F, Pocock SJ, et al. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77(11):1397-407. DOI:10.1016/j.jacc.2021.01.044Pieske B, Patel MJ, Westerhout CM, et al. VICTORIA Study Group. Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial. Eur J Heart Fail. 2019;21(12):1596-604. DOI:10.1002/ejhf.1664Greene SJ, Butler J, Albert NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351-66. DOI:10.1016/j.jacc.2018.04.070Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20(9):1315-22. DOI:10.1002/ejhf.1234Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396(10244):121-8. DOI:10.1016/S0140-6736(20)30748-0Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17. DOI:10.1056/NEJM199909023411001Pitt B, Roniker B. Eplerenone, a novel selective aldosteron receptor antagonist (SARA): dose-finding study in patients with heart failure. J Am Coll Cardiol. 1999;33:188-9A.Zannad F, McMurray JJ, Drexler H, et al. Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12(6):617-22. DOI:10.1093/eurjhf/hfq049Zannad F, McMurray JJ, Krum H, et al. EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11-21. DOI:10.1056/NEJMoa1009492Swedberg K, Zannad F, McMurray JJ, et al. EMPHASIS-HF Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-603. DOI:10.1016/j.jacc.2011.11.063Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-21. DOI:10.1056/NEJMoa030207Pitt B, White H, Nicolau J, et al. Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure. J Am Coll Cardiol. 2005;46(3):425-31. DOI:10.1016/j.jacc.2005.04.038Острый коронарный синдром без подъема сегмента ST электрокардиограммы. Клинические рекомендации Минздрава России, 2020 г. Режим доступа: https://cr.minzdrav.gov.ru/recomend/154_3. Ссылка активна на 11.01.2022 [Ostryi koronarnyi sindrom bez pod'ema segmenta ST elektrokardiogrammy. Klinicheskie rekomendatsii Minzdrava Rossii, 2020 g. Available at: https://cr.minzdrav.gov.ru/recomend/154_3. Accessed: 11.01.2022 (in Russian)].Острый коронарный синдром с подъемом сегмента ST электрокардиограммы. Клинические рекомендации Минздрава России, 2020. Режим доступа: https://cr.minzdrav.gov.ru/recomend/154_3/ Ссылка активна на 11.01.2022 [Ostryi koronarnyi sindrom s pod'emom segmenta ST elektrokardiogrammy. Klinicheskie rekomendatsii Minzdrava Rossi, 2020. Available at: https://cr.minzdrav.gov.ru/recomend/156_1/ Accessed: 11.01.2022 (in Russian)].Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. DOI:10.1093/eurheartj/ehx393Collet JP, Thiele H, Barbato E, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-367. DOI:10.1093/eurheartj/ehaa575Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of patients with non-ST-Elevation Acute Coronary Syndromes. JACC. 2014;64(24):e139-228. DOI:10.1007/s12350-017-1137-zO’Gara P, Kushner F, Aschein D, et al. 2013 ACCF/AHA Guideline for the management of ST-Elevation Myocardial Infarction. JACC. 2013;61(4):e78-140. DOI:10.1161/CIR.0b013e3182742cf6Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005;10(1):23-9. DOI:10.1007/s10741-005-2345-1Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217(1-2):27-31. DOI:10.1016/j.mce.2003.10.005Manolis AA, Manolis TA, Melita H, et al. Eplerenone Versus Spironolactone in Resistant Hypertension: an Efficacy and/or Cost or Just a Men's Issue? Curr Hypertens Rep. 2019;21(3):22. DOI:10.1007/s11906-019-0924-0Margolis J, Gerber RA, Roberts C, Gheorghiade M. Adherence to aldosterone-blocking agents in patients with heart failure. Am J Ther. 2010;17(5):446-54. DOI:10.1097/MJT.0b013e3181ea3213Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia. 2004;47(10):1687-94. DOI:10.1007/s00125-004-1510-8Vukadinović D, Lavall D, Vukadinović AN, et al. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J. 2017;188:99-108. DOI:10.1016/j.ahj.2017.03.011Tang WH, Parameswaran AC, Maroo AP, et al. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc. 2005;80(12):1623-30. DOI:10.4065/80.12.1623Pitt B, Rossignol P. The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure. Expert Opin Drug Saf. 2016;15(5):659-65. DOI:10.1517/14740338.2016.1163335